Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
Department of Radiology, Nihon University School of Medicine, Tokyo, Japan;
In Vivo. 2021 Jul-Aug;35(4):2445-2450. doi: 10.21873/invivo.12523.
BACKGROUND/AIM: We examined the difference between whole-brain radiation therapy (WBRT) for intracranial metastases (IM) from lung cancer as an initial and as a late treatment affecting overall survival (OS).
Thirty-three patients who presented with IM at initial examination who received WBRT as the initial treatment (initial WBRT group) and 47 patients without IM or with asymptomatic IM at initial examination who received WBRT after systemic therapy, between January 2014 and December 2020, were retrospectively analyzed. Patients' OS after WBRT were compared.
Median OS was significantly longer in patients treated with systemic anticancer therapy after WBRT than in patients who were not (176 vs. 47 days, respectively; p<0.001), and systemic anticancer therapy after WBRT was a significant prognostic factor (p<0.001).
Treatment with systemic anticancer therapy after WBRT may prolong the survival of patients who present with IM at initial examination.
背景/目的：我们研究了肺癌颅内转移（IM）患者接受全脑放疗（WBRT）作为初始治疗和晚期治疗对总生存期（OS）的影响。
回顾性分析了 2014 年 1 月至 2020 年 12 月期间，33 例初始检查时出现 IM 并接受 WBRT 作为初始治疗（初始 WBRT 组）的患者和 47 例初始检查时无 IM 或无症状 IM 但接受 WBRT 治疗的患者。比较两组患者 WBRT 后的 OS。
与未接受 WBRT 治疗的患者相比，接受 WBRT 后系统抗癌治疗的患者 OS 显著延长（176 天 vs. 47 天，p<0.001），WBRT 后接受系统抗癌治疗是一个显著的预后因素（p<0.001）。
WBRT 后接受系统抗癌治疗可能延长初始检查时出现 IM 的患者的生存时间。
